24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this crossover, randomized, placebo controlled, double-masked study is to compare the short-term (12 weeks) mean 24-hour IOP control and safety of the new fixed combination (bimatoprost/timolol, BTFC) given PM with placebo once in the morning, versus BTFC given AM with placebo once in the evening versus bimatoprost given in the evening in patients with exfoliative glaucoma (XFG).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination

NCT00941096

Glaucoma Ocular Hypertension

COMPLETED PHASE4

24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice

NCT01448837

Glaucoma

COMPLETED PHASE4

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT01068964

Open-angle Glaucoma Ocular Hypertension

COMPLETED NA

24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination

NCT00331240

Primary Open Angle Glaucoma Exfoliation Syndrome

COMPLETED PHASE3

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332540

Ocular Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY STUDY OBJECTIVES

* To show that the mean 24-hour IOP control obtained with BTFC (morning or evening) is statistically better to that with bimatoprost monotherapy given once on the evening.
* To demonstrate that the fixed combination will provide a significantly better IOP control in the morning when dosed in the evening.
* To test whether the mean 24-hour IOP control obtained with BTFC given once in the evening may be statistically better to that with BTFC given once in the morning.
* To show whether there will be less 24-hour fluctuation of IOP with the evening dosing of BTFC.

STUDY POPULATION

Consecutive newly-diagnosed, or suitably washed-out patients with exfoliative glaucoma (XFG) who exhibit a mean untreated IOP greater than 25 mm Hg at baseline (10:00).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bimatoprost/Timolol AM therapy

Group Type ACTIVE_COMPARATOR

Drug: bimatoprost/timolol fixed combination AM

Intervention Type DRUG

3-month chronic dosing in the morning

Bimatoprost/timolol fixed combination dosed PM

Intervention Type DRUG

Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months

Bimatoprost/Timolol PM therapy

Group Type ACTIVE_COMPARATOR

Drug: bimatoprost/timolol fixed combination AM

Intervention Type DRUG

3-month chronic dosing in the morning

Bimatoprost/timolol fixed combination dosed PM

Intervention Type DRUG

Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug: bimatoprost/timolol fixed combination AM

3-month chronic dosing in the morning

Intervention Type DRUG

Bimatoprost/timolol fixed combination dosed PM

Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient is suffering from XFG (if the patient has bilateral XFG, both eyes will be treated, but the worse eye will be selected for the statistical analysis)
* Patient is older than 39 years and younger than 85 years
* Patient is able and willing to participate in the study for the whole duration of the follow up. Will sign the consent form.
* At screening the untreated IOP at 10:00 (± 1 hr) is greater than 25 mm Hg and lower than 40 mm Hg
* After bimatoprost run-in therapy the treated IOP at 10:00 (± 1 hr) is greater than 19 mm Hg

Minimum Eligible Age

39 Years

Maximum Eligible Age

81 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No